Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | ECE1 | P42892 | 8/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8825328 | 0.84 | KDM4E (0.46) | KDM4EL3MBTL1ECE1ALDH1A1MAPK1 | |
| SCHEMBL7234015 | 0.79 | KDM4E (0.68) | KDM4EL3MBTL1ECE1ALOX15ALDH1A1 | |
| SCHEMBL13363185 | 0.79 | KDM4E (0.68) | KDM4EL3MBTL1ECE1ALOX15ALDH1A1 | |
| SCHEMBL7225742 | 0.79 | KDM4E (1.00) | KDM4EL3MBTL1ECE1ALOX15ALDH1A1 | |
| SCHEMBL7226508 | 0.78 | KDM4E (0.66) | KDM4EL3MBTL1ECE1ALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7235077 | 0.78 | KDM4E (0.66) | KDM4EL3MBTL1ECE1ALOX15ALDH1A1 | |
| SCHEMBL29375401 | 0.78 | KDM4E (0.66) | KDM4EL3MBTL1ECE1ALOX15ALDH1A1 | |
| SCHEMBL1759891 | 0.78 | KDM4E (0.66) | KDM4EL3MBTL1ECE1ALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7225758 | 0.76 | KDM4E (0.64) | KDM4EL3MBTL1ECE1ALOX15ALDH1A1 | |
| SCHEMBL9174517 | 0.75 | KDM4E (0.41) | KDM4EL3MBTL1ECE1ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281060-B2 | Remodilins for airway remodeling and organ fibrosis | THE UNIVERSITY OF CHICAGO (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240415851-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | THE UNIVERSITY OF CHICAGO (US) | 2024-12-19 | — | — | US | disclosed |
| US-20220177422-A1 | REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS | THE UNIVERSITY OF CHICAGO (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220040207-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | THE UNIVERSITY OF CHICAGO (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3946301-A1 | REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS | The University of Chicago (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020206109-A1 | REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS | THE UNIVERSITY OF CHICAGO (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020206118-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | THE UNIVERSITY OF CHICAGO (US) | 2020-10-08 | — | — | WO | disclosed |
| US-5624943-A | Pyridine compounds which are useful as leukotriene-B4 -antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-04-29 | — | — | US | disclosed |
| EP-0651745-A1 | NEW PYRIDINE DERIVATIVES AS LEUKCOTRIENE B 4? ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002464-A1 | NEW PYRIDINE DERIVATIVES AS LEUKCOTRIENE B4 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220040207-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | HIF1AN, RHOXF2, HIF1A | KDM4E 2561/4885L3MBTL1 3750/4885ECE1 720/4885 |
| US-20220177422-A1 | REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS | MYLK, MFAP1, FIBP | KDM4E 2386/4885L3MBTL1 4125/4885ECE1 559/4885 |
| US-12281060-B2 | Remodilins for airway remodeling and organ fibrosis | MYLK, MFAP1, FIBP | KDM4E 2386/4885L3MBTL1 4125/4885ECE1 559/4885 |
| US-20240415851-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | HIF1AN, RHOXF2, HIF1A | KDM4E 2561/4885L3MBTL1 3750/4885ECE1 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.